Corticosteroids and immunosuppressants affect bone metabolism, wound healing, and immune defence — three factors critical to implant osseointegration. Nevertheless, implant treatment is possible for most patients when the protocol is adapted: dose optimisation, extended hygiene management, longer healing times, and — crucially — precise digital planning that reduces surgical trauma to a minimum.
Rheumatoid arthritis, Crohn's disease, lupus erythematosus, multiple sclerosis — millions of people in Austria and Germany live with autoimmune diseases and depend permanently on corticosteroids or immunosuppressants. Many of these patients lose teeth due to the underlying disease itself or through medication side effects and ask: is a dental implant even an option for me?
The honest answer: yes — but with considerably greater planning effort than for healthy patients. This article explains which medications create which risks, what the clinical protocol looks like, and why digital implant planning is not a comfort solution but a medical necessity for immunosuppressed patients.
How Corticosteroids and Immunosuppressants Affect Implant Osseointegration
Glucocorticoids (cortisone, prednisolone, dexamethasone) act on three mechanisms critical to osseointegration: they inhibit osteoblast activity, increase osteoclast activity, and reduce collagen synthesis. The result is diminished new bone formation around the implant — precisely the process needed for stable integration.
| Drug Class | Examples | Main Risk | Critical Threshold |
|---|---|---|---|
| Glucocorticoids | Prednisolone, Dexamethasone, Cortisone | Bone loss, delayed wound healing | ≥7.5 mg prednisolone/day (long-term) |
| Antimetabolites | Methotrexate, Azathioprine | Wound healing disorder, infection risk | High doses / combination with corticosteroids |
| Calcineurin Inhibitors | Ciclosporin, Tacrolimus | Gingival hyperplasia, infection risk | Long-term therapy |
| TNF-α Inhibitors | Adalimumab, Etanercept, Infliximab | Increased infection risk (peri-implantitis) | Active therapy |
| mTOR Inhibitors | Sirolimus, Everolimus | Severely delayed wound healing | Any dose — relative contraindication |
| Mycophenolate Mofetil | CellCept, Myfortic | Wound healing disorder, infection risk | Combination with other immunosuppressants |
Digital Planning as a Medical Necessity for Immunosuppressed Patients
In immunosuppressed patients, surgical trauma is the decisive risk factor: the smaller the surgical intervention, the lower the infection risk and the better the healing prognosis. Digital implant planning makes a measurable clinical contribution here — not as a technological upgrade, but as a risk minimisation strategy.
Digital volume tomography (DVT) enables precise assessment of bone density in Hounsfield units. In corticosteroid-induced osteoporosis, areas with sufficient bone density for implant positioning are identified — without exploratory surgery.
Computer-guided drill templates enable flapless implantation — surgical trauma is reduced to a minimum. Less trauma means less wound surface, lower infection risk, and faster healing.
DVT comparison scans document bone apposition around the implant over time. In immunosuppressed patients, this enables early detection of healing problems — before clinical symptoms appear.
Corticosteroids must never be abruptly discontinued after long-term therapy — this can trigger a life-threatening Addison's crisis (acute adrenal insufficiency). Dose reduction must be gradual and in coordination with the treating physician. Always inform your implantologist fully about all medications you are taking.
Common Autoimmune Conditions and Their Specific Implications
| Condition | Typical Medication | Implant Consideration | Prognosis |
|---|---|---|---|
| Rheumatoid Arthritis | MTX, biologics, corticosteroids | Dry mouth from MTX, elevated peri-implantitis risk | Good with stable disease |
| Crohn's Disease / IBD | Azathioprine, biologics, corticosteroids | Malnutrition → check bone quality | Good in remission |
| Lupus Erythematosus | Hydroxychloroquine, corticosteroids, MTX | Oral mucosal lesions, xerostomia | Individual — avoid flare phases |
| Multiple Sclerosis | Interferons, natalizumab, corticosteroids (flare) | Corticosteroids mainly during flares → timing | Good outside flare phases |
| Psoriatic Arthritis | MTX, biologics, NSAIDs | Similar to RA — coordinate biologic pause | Good with stable disease |
| Organ Transplantation | Ciclosporin, tacrolimus, MMF, corticosteroids | Gingival hyperplasia, highest infection risk | Possible, but highest requirements |
Conclusion: Possible — But Only with the Right Protocol
Corticosteroids and immunosuppressants measurably increase implant risk — but they do not rule out successful treatment for most patients. What matters is an individually adapted protocol: dose optimisation in coordination with the treating physician, extended hygiene management, longer healing times, and precise digital planning that minimises surgical trauma.
Related topic: Thyroid disorders (Hashimoto, hyperthyroidism) also affect bone metabolism and implant healing. Article 24: Dental Implant and Thyroid Disease →
Related topic: HIV-positive patients on antiretroviral therapy (ART) also receive immunomodulators — with their own risk profile for implant osseointegration. Article 30: Dental Implant with HIV/AIDS →
Related topic: Heart transplant patients often receive corticosteroids — a combined risk profile of immunosuppression and cardiovascular limitations. Article 31: Dental Implant with Heart Failure and Pacemaker →
Related topic: Sjögren's syndrome and lupus erythematosus are often treated with hydroxychloroquine — not a classic immunosuppressant, but with direct impact on xerostomia and osseointegration. Article 32: Dental Implant with Autoimmune Diseases (Lupus, Sjögren) →
Institut für Implantologie und digitale Zahnmedizin Wien
Fachärztliches Team IIDZ Wien
Weitere Artikel
Thematisch verwandt
Hinweis: Diese Inhalte dienen ausschließlich der allgemeinen Information und ersetzen keine individuelle zahnärztliche Beratung. Das Institut für Implantologie und digitale Zahnmedizin Wien ist eine gemeinnützige, unabhängige Wissenschaftsplattform — kein Behandlungsbetrieb. Alle Angaben entsprechen dem aktuellen Stand der wissenschaftlichen Literatur; individuelle Behandlungsentscheidungen müssen stets mit einem approbierten Zahnarzt oder Facharzt getroffen werden.